$EPZM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Epizyme, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Epizyme, Inc.. Get notifications about new insider transactions in Epizyme, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 07 2021 | EPZM | Epizyme, Inc. | Kutok Jeffery | Chief Scientific Of ... | Sell | S | 8.80 | 2,029 | 17,855 | 54,028 | 56.1 K to 54 K (-3.62 %) |
Apr 01 2021 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 8.71 | 1,723 | 15,007 | 11,282 | 9.6 K to 11.3 K (+18.02 %) |
Apr 01 2021 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 8.71 | 2,727 | 23,752 | 153,627 | 150.9 K to 153.6 K (+1.81 %) |
Feb 05 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 11.21 | 3,890 | 43,607 | 331,977 | 335.9 K to 332 K (-1.16 %) |
Feb 05 2021 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 11.21 | 969 | 10,862 | 104,341 | 105.3 K to 104.3 K (-0.92 %) |
Feb 05 2021 | EPZM | Epizyme, Inc. | Vakiener Victoria | Chief Commercial Of ... | Sell | S | 11.21 | 817 | 9,159 | 52,685 | 53.5 K to 52.7 K (-1.53 %) |
Feb 02 2021 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Option Exercise | A | 11.02 | 141,135 | 1,555,308 | 141,135 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 29,583 | 0 | 105,310 | 75.7 K to 105.3 K (+39.07 %) |
Feb 02 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 11.02 | 417,443 | 4,600,222 | 417,443 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 87,500 | 0 | 335,867 | 248.4 K to 335.9 K (+35.23 %) |
Feb 02 2021 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Option Exercise | A | 11.02 | 11,550 | 127,281 | 11,550 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 7,700 | 0 | 13,658 | 6 K to 13.7 K (+129.24 %) |
Feb 02 2021 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Option Exercise | A | 11.02 | 124,239 | 1,369,114 | 124,239 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 26,041 | 0 | 54,486 | 28.4 K to 54.5 K (+91.55 %) |
Feb 02 2021 | EPZM | Epizyme, Inc. | Vakiener Victoria | Chief Commercial Of ... | Option Exercise | A | 11.02 | 121,754 | 1,341,729 | 121,754 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Vakiener Victoria | Chief Commercial Of ... | Grant | A | 0.00 | 25,520 | 0 | 53,502 | 28 K to 53.5 K (+91.20 %) |
Feb 02 2021 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | A | 11.02 | 134,178 | 1,478,642 | 134,178 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 28,125 | 0 | 84,082 | 56 K to 84.1 K (+50.26 %) |
Feb 02 2021 | EPZM | Epizyme, Inc. | Kutok Jeffery | Chief Scientific Of ... | Option Exercise | A | 11.02 | 136,663 | 1,506,026 | 136,663 | |
Feb 02 2021 | EPZM | Epizyme, Inc. | Kutok Jeffery | Chief Scientific Of ... | Grant | A | 0.00 | 28,645 | 0 | 56,057 | 27.4 K to 56.1 K (+104.50 %) |
Jan 27 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 11.41 | 6,069 | 69,247 | 248,367 | 254.4 K to 248.4 K (-2.39 %) |
Jan 27 2021 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 11.41 | 2,872 | 32,770 | 55,957 | 58.8 K to 56 K (-4.88 %) |
Jan 27 2021 | EPZM | Epizyme, Inc. | Vakiener Victoria | Chief Commercial Of ... | Sell | S | 11.41 | 599 | 6,835 | 27,982 | 28.6 K to 28 K (-2.10 %) |
Jan 27 2021 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 11.41 | 2,872 | 32,770 | 75,727 | 78.6 K to 75.7 K (-3.65 %) |
Jan 05 2021 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 10.86 | 1,024 | 11,121 | 9,559 | 8.5 K to 9.6 K (+12.00 %) |
Jan 05 2021 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 10.86 | 2,158 | 23,436 | 88,183 | 86 K to 88.2 K (+2.51 %) |
Nov 13 2020 | EPZM | Epizyme, Inc. | GOLDFISCHER CARL | Director | Buy | P | 12.07 | 5,000 | 60,350 | 5,000 | 0 to 5 K |
Oct 01 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 11.93 | 1,965 | 23,442 | 86,025 | 84.1 K to 86 K (+2.34 %) |
Oct 01 2020 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 11.93 | 933 | 11,131 | 8,535 | 7.6 K to 8.5 K (+12.27 %) |
Sep 28 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 12.66 | 50,000 | 633,000 | 50,000 | |
Sep 03 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Option Exercise | A | 12.79 | 6,650 | 85,054 | 6,650 | |
Sep 03 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 12.88 | 543 | 6,994 | 5,958 | 6.5 K to 6 K (-8.35 %) |
Sep 03 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 12.77 | 971 | 12,400 | 6,501 | 7.5 K to 6.5 K (-13.00 %) |
Aug 21 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Option Exercise | M | 0.00 | 7,055 | 0 | 21,162 | |
Aug 21 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Payment of Exercise | F | 12.55 | 2,091 | 26,242 | 26,906 | 29 K to 26.9 K (-7.21 %) |
Aug 21 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Buy | M | 0.00 | 7,055 | 0 | 28,997 | 21.9 K to 29 K (+32.15 %) |
Jul 01 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 16.06 | 1,459 | 23,432 | 84,060 | 82.6 K to 84.1 K (+1.77 %) |
Jul 01 2020 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 16.06 | 693 | 11,130 | 7,602 | 6.9 K to 7.6 K (+10.03 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 16.15 | 317 | 5,120 | 4,838 | 5.2 K to 4.8 K (-6.15 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 1,050 | 0 | 5,155 | 4.1 K to 5.2 K (+25.58 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 16.15 | 4,773 | 77,084 | 250,098 | 254.9 K to 250.1 K (-1.87 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 10,500 | 0 | 254,871 | 244.4 K to 254.9 K (+4.30 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Sell | S | 16.15 | 1,805 | 29,151 | 21,942 | 23.7 K to 21.9 K (-7.60 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 6,000 | 0 | 23,747 | 17.7 K to 23.7 K (+33.81 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 16.15 | 1,805 | 29,151 | 78,611 | 80.4 K to 78.6 K (-2.24 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 6,000 | 0 | 80,416 | 74.4 K to 80.4 K (+8.06 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 16.15 | 2,728 | 44,057 | 57,507 | 60.2 K to 57.5 K (-4.53 %) |
Jun 30 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 6,000 | 0 | 60,235 | 54.2 K to 60.2 K (+11.06 %) |
Jun 26 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | P | 16.03 | 62,019 | 994,165 | 82,601 | 20.6 K to 82.6 K (+301.33 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 67,662 | 0 | 106,959 | 39.3 K to 107 K (+172.18 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | M | 8.98 | 10,000 | 89,800 | 323,333 | |
Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 22.00 | 10,000 | 220,000 | 244,371 | 254.4 K to 244.4 K (-3.93 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 22.00 | 10,000 | 220,000 | 254,371 | 264.4 K to 254.4 K (-3.78 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Buy | M | 8.98 | 10,000 | 89,800 | 264,371 | 254.4 K to 264.4 K (+3.93 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | M | 9.58 | 68,651 | 657,677 | 104,787 | |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | M | 12.45 | 2,289 | 28,498 | 107,577 | |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | M | 9.12 | 41,063 | 374,495 | 110,557 | |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 21.65 | 68,651 | 1,486,294 | 51,798 | 120.4 K to 51.8 K (-57.00 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Buy | M | 9.58 | 68,651 | 657,677 | 120,449 | 51.8 K to 120.4 K (+132.54 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 22.00 | 2,289 | 50,358 | 51,798 | 54.1 K to 51.8 K (-4.23 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Buy | M | 12.45 | 2,289 | 28,498 | 54,087 | 51.8 K to 54.1 K (+4.42 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 20.50 | 41,063 | 841,792 | 51,798 | 92.9 K to 51.8 K (-44.22 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Buy | M | 9.12 | 41,063 | 374,495 | 92,861 | 51.8 K to 92.9 K (+79.28 %) |
Jun 02 2020 | EPZM | Epizyme, Inc. | Legorreta Pablo G. | Director | Option Exercise | A | 17.55 | 14,103 | 247,508 | 14,103 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | Giordano Michael F | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | Allen Andrew R | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | Richon Victoria | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | Bogle Grant C. | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | GOLDFISCHER CARL | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | POPS RICHARD F | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Jun 02 2020 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Apr 03 2020 | EPZM | Epizyme, Inc. | Kutok Jeffery | Chief Scientific Of ... | Option Exercise | A | 13.68 | 131,580 | 1,800,014 | 131,580 | |
Apr 03 2020 | EPZM | Epizyme, Inc. | Kutok Jeffery | Chief Scientific Of ... | Grant | A | 0.00 | 27,412 | 0 | 27,412 | 0 to 27.4 K |
Apr 02 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 15.51 | 1,512 | 23,451 | 20,582 | 19.1 K to 20.6 K (+7.93 %) |
Apr 02 2020 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 15.51 | 717 | 11,121 | 6,909 | 6.2 K to 6.9 K (+11.58 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 15.28 | 212 | 3,239 | 4,961 | 5.2 K to 5 K (-4.10 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 1,556 | 0 | 5,173 | 3.6 K to 5.2 K (+43.02 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Sell | S | 15.28 | 1,243 | 18,993 | 15,437 | 16.7 K to 15.4 K (-7.45 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 1,690 | 0 | 16,680 | 15 K to 16.7 K (+11.27 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 15.28 | 1,243 | 18,993 | 51,798 | 53 K to 51.8 K (-2.34 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 1,563 | 0 | 53,041 | 51.5 K to 53 K (+3.04 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.14 | 73,409 | 1,184,821 | 73,409 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 9.12 | 48,727 | 444,390 | 298,737 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 15.28 | 212 | 3,239 | 4,961 | 5.2 K to 5 K (-4.10 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 12.45 | 2,371 | 29,519 | 333,333 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 1,556 | 0 | 5,173 | 3.6 K to 5.2 K (+43.02 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 8.98 | 79,167 | 710,920 | 333,333 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 15.28 | 3,285 | 50,195 | 254,371 | 257.7 K to 254.4 K (-1.27 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Sell | S | 15.28 | 1,243 | 18,993 | 15,437 | 16.7 K to 15.4 K (-7.45 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 257,656 | 250.7 K to 257.7 K (+2.79 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 1,690 | 0 | 16,680 | 15 K to 16.7 K (+11.27 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 113,393 | 0 | 250,656 | 137.3 K to 250.7 K (+82.61 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | J | 0.00 | 56,537 | 0 | 80,726 | 137.3 K to 80.7 K (-41.19 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 15.28 | 1,243 | 18,993 | 51,798 | 53 K to 51.8 K (-2.34 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 15.28 | 1,243 | 18,993 | 71,991 | 73.2 K to 72 K (-1.70 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 1,563 | 0 | 53,041 | 51.5 K to 53 K (+3.04 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 1,575 | 0 | 73,234 | 71.7 K to 73.2 K (+2.20 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.14 | 73,409 | 1,184,821 | 73,409 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 9.12 | 48,727 | 444,390 | 298,737 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 12.45 | 2,371 | 29,519 | 333,333 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 8.98 | 79,167 | 710,920 | 333,333 | |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 15.28 | 3,285 | 50,195 | 254,371 | 257.7 K to 254.4 K (-1.27 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 257,656 | 250.7 K to 257.7 K (+2.79 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 113,393 | 0 | 250,656 | 137.3 K to 250.7 K (+82.61 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | J | 0.00 | 56,537 | 0 | 80,726 | 137.3 K to 80.7 K (-41.19 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 15.28 | 1,243 | 18,993 | 71,991 | 73.2 K to 72 K (-1.70 %) |
Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 1,575 | 0 | 73,234 | 71.7 K to 73.2 K (+2.20 %) |
Mar 18 2020 | EPZM | Epizyme, Inc. | Allen Andrew R | Director | Option Exercise | M | 9.33 | 12,500 | 116,625 | 0 | |
Mar 18 2020 | EPZM | Epizyme, Inc. | Allen Andrew R | Director | Buy | M | 9.33 | 12,500 | 116,625 | 12,500 | 0 to 12.5 K |
Mar 05 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 22.18 | 996 | 22,091 | 3,617 | 4.6 K to 3.6 K (-21.59 %) |
Feb 13 2020 | EPZM | Epizyme, Inc. | Legorreta Pablo G. | Director | Grant | A | 20.00 | 2,500,000 | 50,000,000 | 9,166,667 | 6.7 M to 9.2 M (+37.50 %) |
Feb 05 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 21.39 | 252,956 | 5,410,729 | 252,956 | |
Feb 05 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 52,595 | 0 | 137,263 | 84.7 K to 137.3 K (+62.12 %) |
Feb 05 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Option Exercise | A | 21.39 | 56,213 | 1,202,396 | 56,213 | |
Feb 05 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 11,688 | 0 | 51,478 | 39.8 K to 51.5 K (+29.37 %) |
Feb 05 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Option Exercise | A | 21.39 | 61,834 | 1,322,629 | 61,834 | |
Feb 05 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 12,856 | 0 | 71,659 | 58.8 K to 71.7 K (+21.86 %) |
Feb 05 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Option Exercise | A | 21.39 | 11,588 | 247,867 | 11,588 | |
Feb 05 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 2,575 | 0 | 3,617 | 1 K to 3.6 K (+247.12 %) |
Feb 05 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Option Exercise | A | 21.39 | 56,213 | 1,202,396 | 56,213 | |
Feb 05 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 11,688 | 0 | 14,990 | 3.3 K to 15 K (+353.97 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 20.44 | 2,630 | 53,757 | 58,803 | 61.4 K to 58.8 K (-4.28 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 24.64 | 1,843 | 45,412 | 61,433 | 63.3 K to 61.4 K (-2.91 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 5,000 | 0 | 63,276 | 58.3 K to 63.3 K (+8.58 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Payment of Exercise | F | 22.40 | 2,395 | 53,648 | 39,790 | 42.2 K to 39.8 K (-5.68 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 24.64 | 1,847 | 45,510 | 42,185 | 44 K to 42.2 K (-4.19 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 5,000 | 0 | 44,032 | 39 K to 44 K (+12.81 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 20.44 | 6,074 | 124,153 | 84,668 | 90.7 K to 84.7 K (-6.69 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 24.62 | 3,002 | 73,909 | 90,742 | 93.7 K to 90.7 K (-3.20 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 8,750 | 0 | 93,744 | 85 K to 93.7 K (+10.29 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 24.63 | 330 | 8,128 | 1,042 | 1.4 K to 1 K (-24.05 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 875 | 0 | 1,372 | 497 to 1.4 K (+176.06 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Payment of Exercise | F | 26.72 | 1,698 | 45,371 | 3,302 | 5 K to 3.3 K (-33.96 %) |
Jan 27 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Jan 03 2020 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 24.60 | 452 | 11,119 | 6,192 | 5.7 K to 6.2 K (+7.87 %) |
Dec 06 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Option Exercise | A | 16.61 | 34,978 | 580,985 | 34,978 | |
Dec 06 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 22,577 | 0 | 58,276 | 35.7 K to 58.3 K (+63.24 %) |
Nov 08 2019 | EPZM | Epizyme, Inc. | Legorreta Pablo G. | Director | Option Exercise | A | 13.51 | 34,408 | 464,852 | 34,408 | |
Oct 02 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 10.32 | 2,271 | 23,437 | 18,118 | 15.8 K to 18.1 K (+14.33 %) |
Sep 04 2019 | EPZM | Epizyme, Inc. | Bogle Grant C. | Director | Option Exercise | A | 12.54 | 37,075 | 464,921 | 37,075 | |
Sep 04 2019 | EPZM | Epizyme, Inc. | Richon Victoria | Director | Option Exercise | A | 12.54 | 37,075 | 464,921 | 37,075 | |
Aug 21 2019 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Option Exercise | A | 0.00 | 28,217 | 0 | 28,217 | |
Aug 21 2019 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Option Exercise | A | 13.86 | 132,225 | 1,832,639 | 132,225 | |
Jul 02 2019 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 12.55 | 887 | 11,132 | 4,662 | 3.8 K to 4.7 K (+23.50 %) |
Jun 28 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | S | 12.43 | 52,473 | 652,134 | 0 | 52.5 K to 0 (-100.00 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | S | 12.85 | 52,472 | 674,176 | 52,473 | 104.9 K to 52.5 K (-50.00 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | S | 13.31 | 52,472 | 698,649 | 104,945 | 157.4 K to 104.9 K (-33.33 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 157,417 | 0 | 157,417 | 0 to 157.4 K |